Details of the Drug

General Information of Drug (ID: DMAIGTE)

Drug Name
SurVaxM
Indication
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 2 [1]
Multiple myeloma 2A83 Phase 1 [2]
Cross-matching ID
TTD ID
D0KQ8W
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis inhibitor survivin (BIRC5) TTTPU1G BIRC5_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Glioblastoma of brain
ICD Disease Classification 2A00.00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Apoptosis inhibitor survivin (BIRC5) DTT BIRC5 1.67E-190 1.63 5.29
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04013672) Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)